Both companies have favorable financials and unique value propositions for consumers in their markets. DexCom is capitalizing on the ways that its devices can help patients in virtually all stages ...

NEW YORK, NY / ACCESSWIRE / July 27, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the...

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of fed...

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance.

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federa...

DexCom reported disappointing earnings, missing estimates by 4% and lowering full-year growth expectations by ~$200 million. Sales in the U.S. market slowed, while international markets saw anemic ...

Shares in Dexcom (DXCM) lost more than a third of their value in extended trading Thursday after the medical devices company posted second-quarter results that came in below Wall Street expectation...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) investors concerning the Company's po...

DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago.

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investors are showing varying degrees of appetite for the telehealth and diabetes care industries. Teladoc has undergone major changes in recent years, and investors are warily eyeing its path forw...

Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.